CN112996764B - 螯合aazta缀合物及其配合物 - Google Patents

螯合aazta缀合物及其配合物 Download PDF

Info

Publication number
CN112996764B
CN112996764B CN201980074119.4A CN201980074119A CN112996764B CN 112996764 B CN112996764 B CN 112996764B CN 201980074119 A CN201980074119 A CN 201980074119A CN 112996764 B CN112996764 B CN 112996764B
Authority
CN
China
Prior art keywords
aazta
tate
metal
nta
ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980074119.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN112996764A (zh
Inventor
Z·巴拉尼艾
S·吉亚尼
A·麦欧驰
I·哈瓦拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco Imaging SpA
Original Assignee
Bracco Imaging SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging SpA filed Critical Bracco Imaging SpA
Publication of CN112996764A publication Critical patent/CN112996764A/zh
Application granted granted Critical
Publication of CN112996764B publication Critical patent/CN112996764B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201980074119.4A 2018-11-12 2019-11-12 螯合aazta缀合物及其配合物 Active CN112996764B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18205796 2018-11-12
EP18205796.8 2018-11-12
PCT/EP2019/081014 WO2020099398A1 (en) 2018-11-12 2019-11-12 Chelating aazta conjugates and complexes thereof

Publications (2)

Publication Number Publication Date
CN112996764A CN112996764A (zh) 2021-06-18
CN112996764B true CN112996764B (zh) 2023-11-21

Family

ID=64308553

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980074119.4A Active CN112996764B (zh) 2018-11-12 2019-11-12 螯合aazta缀合物及其配合物

Country Status (5)

Country Link
US (1) US11684682B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880635B1 (cg-RX-API-DMAC7.html)
JP (2) JP7744240B2 (cg-RX-API-DMAC7.html)
CN (1) CN112996764B (cg-RX-API-DMAC7.html)
WO (1) WO2020099398A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3880635B1 (en) * 2018-11-12 2023-01-04 Bracco Imaging SPA Chelating aazta conjugate, complexes thereof and use
DE102021111452B3 (de) * 2021-05-04 2022-07-28 Positron Precision GmbH Markierungsvorläufer und Radiotracer für neuroendokrine Theranostik
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
IL317339A (en) 2022-07-28 2025-01-01 Bracco Imaging Spa 1,4-Bis-(2-hydroxybenzyl)-1,4,7-triazaciconanone derivatives and similar compounds as ligands in iron(III) complexes for use as MRI contrast agents
CN122228249A (zh) 2023-12-06 2026-06-16 伯拉考成像股份公司 用于与铁离子过量和/或蓄积相关的疾病的化合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101233117A (zh) * 2005-06-24 2008-07-30 伯拉考成像股份公司 能够与金属离子配合的多齿氮杂配体及其在诊断和治疗中的应用
CN101558081A (zh) * 2006-12-11 2009-10-14 伯拉考成像股份公司 用于诊断和治疗应用的纤维蛋白结合肽缀合体
CN101641366A (zh) * 2007-02-27 2010-02-03 伯拉考成像股份公司 诊断和放射治疗造影剂和其制备方法
EP3177598A1 (en) * 2014-07-28 2017-06-14 Institut National de la Sante et de la Recherche Medicale (INSERM) Macrocyclic complexes, their process of preparation and use as pet imaging agents
CN107106711A (zh) * 2014-10-17 2017-08-29 Scv公司 用于诊断和治疗骨病的共轭二膦酸盐

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20011518A1 (it) 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
EP1765812B1 (en) 2004-07-02 2009-04-29 Bracco Imaging S.p.A Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain a chelating moiety with polyhydroxylated substituents
FR2914304B1 (fr) * 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
EP2639227A1 (en) 2012-03-14 2013-09-18 Bracco Imaging S.p.A A new class of diazepine derivative chelating agents and complexes with paramagnetic metals as MRI contrast agents
CN108473538B (zh) * 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
EP3880635B1 (en) * 2018-11-12 2023-01-04 Bracco Imaging SPA Chelating aazta conjugate, complexes thereof and use
CN213135750U (zh) * 2020-08-28 2021-05-07 苏州信毅捷自动化科技有限公司 一种便于拆卸的曲柄压装设备

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101233117A (zh) * 2005-06-24 2008-07-30 伯拉考成像股份公司 能够与金属离子配合的多齿氮杂配体及其在诊断和治疗中的应用
CN101558081A (zh) * 2006-12-11 2009-10-14 伯拉考成像股份公司 用于诊断和治疗应用的纤维蛋白结合肽缀合体
CN101573143A (zh) * 2006-12-11 2009-11-04 伯拉考成像股份公司 纤维蛋白结合肽及其缀合体
CN101641366A (zh) * 2007-02-27 2010-02-03 伯拉考成像股份公司 诊断和放射治疗造影剂和其制备方法
EP3177598A1 (en) * 2014-07-28 2017-06-14 Institut National de la Sante et de la Recherche Medicale (INSERM) Macrocyclic complexes, their process of preparation and use as pet imaging agents
CN107106711A (zh) * 2014-10-17 2017-08-29 Scv公司 用于诊断和治疗骨病的共轭二膦酸盐

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthese, Radiomarkierung sowie in vitro- und in vivo- Evaluierung verschiedener Chelator-Biomolekül- Systeme mit den Radionukliden 68Ga, 89Zr und 177Lu;Johannes Nagel;《Dissertation》;20170817;第23页第1段、第49页第1段、第90页第2段、第1.5.1部分、Abbildung 11、第160-161页 *

Also Published As

Publication number Publication date
JP7744240B2 (ja) 2025-09-25
EP3880635B1 (en) 2023-01-04
WO2020099398A1 (en) 2020-05-22
EP3880635A1 (en) 2021-09-22
JP2022507214A (ja) 2022-01-18
CN112996764A (zh) 2021-06-18
US11684682B2 (en) 2023-06-27
US20220016275A1 (en) 2022-01-20
JP2023179429A (ja) 2023-12-19

Similar Documents

Publication Publication Date Title
CN114401947B (zh) 靶向前列腺特异性膜抗原的放射性标记化合物
US11684682B2 (en) Chelating AAZTA conjugates and complexes thereof
US12622984B2 (en) High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
Honarvar et al. Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors
Mishiro et al. RGD peptide-conjugated dodecaborate with the Ga-DOTA complex: a preliminary study for the development of theranostic agents for boron neutron capture therapy and its companion diagnostics
EP3268337B1 (en) Methods and kits for preparing radionuclide complexes
KR20220063214A (ko) Grpr 길항제의 방사성표지 방법 및 이의 키트
JP7646637B2 (ja) 画像化及び治療用組成物
US20110117012A1 (en) Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors
US20220233726A1 (en) Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
Joaqui-Joaqui et al. Catechol-based functionalizable ligands for gallium-68 positron emission tomography imaging
CN114364690A (zh) 用于诊断和治疗的新型放射性标记的cxcr4靶向化合物
JP2025506001A (ja) ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物
CN118632858A (zh) 抑胃肽受体配体
CN118119581A (zh) 放射性药物、其生产方法以及在疾病治疗、诊断和成像中的用途
Ishizaki et al. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives
JPH07505621A (ja) 外科手術中における腫瘍組織の検出および探知法
WO2025171887A1 (en) Radiolabeled complexes and pharmaceutical compositions including the same
Floresta et al. RSC Medicinal Chemistry
Thapa Fluorine-18 labeling and simultaneous glycosylation of the model peptide demobesin 1 by the novel prosthetic group, keto-[18 F] FDG
Deberle Development of radiolabeled small molecules and peptides towards targeted radionuclide therapy
CN121652225A (zh) 一种c-met靶向肽、包含其的多肽、分子探针、结合物及其用途
Heppeler et al. Metal-Ion-Dependent Biological Properties of a Chelator-Derived SomatoACHTUNGTRENNUNGstatin Analogue for Tumour Targeting
EA052134B1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant